The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The new centre brings advanced corneal procedures pioneered in India
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
Dr. Reddy's commits to achieving Net Zero greenhouse gas emissions across its value chain by FY 2045
The product will be marketed by Dr. Reddy's Laboratories Inc.
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Subscribe To Our Newsletter & Stay Updated
